PowerShow.com
  • Help
  • Preferences
  • Sign up
  • Log in
Advanced
Free template

Dyslipidemia Drug PowerPoint PPT Presentations

Grid List
All Time
All TimeAdded TodayAdded This WeekAdded This Month
Show:
Recommended
RecommendedRelevanceLatestHighest RatedMost Viewed
Sort by:
Featured Presentations
Search Results
Drugs and Dyslipidemias (statins and other lipid and atherosclerosis-modifying drugs) PowerPoint PPT Presentation
Drugs and Dyslipidemias (statins and other lipid and atherosclerosis-modifying drugs) - Drugs and Dyslipidemias (statins and other lipid and atherosclerosis-modifying drugs) October 18, 2006 Frank F. Vincenzi Atherosclerosis Associated with many ...
Drugs and Dyslipidemias (statins and other lipid and atherosclerosis-modifying drugs) October 18, 2006 Frank F. Vincenzi Atherosclerosis Associated with many ...
| PowerPoint PPT presentation | free to view
Global Dyslipidemia Drugs Market Insight and Forecast to 2026 PowerPoint PPT Presentation
Global Dyslipidemia Drugs Market Insight and Forecast to 2026 - The research team projects that the Dyslipidemia Drugs market size will grow from XXX in 2019 to XXX by 2026, at an estimated CAGR of XX. The base year considered for the study is 2019, and the market size is projected from 2020 to 2026.
The research team projects that the Dyslipidemia Drugs market size will grow from XXX in 2019 to XXX by 2026, at an estimated CAGR of XX. The base year considered for the study is 2019, and the market size is projected from 2020 to 2026.
| PowerPoint PPT presentation | free to download
Global Dyslipidemia Drugs Industry 2016 Deep Market Research Report PowerPoint PPT Presentation
Global Dyslipidemia Drugs Industry 2016 Deep Market Research Report - Global Dyslipidemia Drugs Industry 2016 - Research Beam offers Dyslipidemia Drugs Industry Analysis Report by QYResearch [Report Price $2800]" Source: http://www.researchbeam.com/global-dyslipidemia-drugs-industry-deep-research-report-market
Global Dyslipidemia Drugs Industry 2016 - Research Beam offers Dyslipidemia Drugs Industry Analysis Report by QYResearch [Report Price $2800]" Source: http://www.researchbeam.com/global-dyslipidemia-drugs-industry-deep-research-report-market
| PowerPoint PPT presentation | free to download
New Drugs Drugs introduced in 2001 contributed 1 percent to PowerPoint PPT Presentation
New Drugs Drugs introduced in 2001 contributed 1 percent to - New Drugs Drugs introduced in 2001 contributed 1 percent to 2000-2001 trend Two-thirds of this contribution is attributable to increased utilization Drugs introduced ...
New Drugs Drugs introduced in 2001 contributed 1 percent to 2000-2001 trend Two-thirds of this contribution is attributable to increased utilization Drugs introduced ...
| PowerPoint PPT presentation | free to download
DYSLIPIDEMIA PowerPoint PPT Presentation
DYSLIPIDEMIA - Core contains TG, phospholipid & cholesterol. 4 classes of lipoproteins ... loss and drug therapy are the mainstay of treatment, while exercise training is ...
Core contains TG, phospholipid & cholesterol. 4 classes of lipoproteins ... loss and drug therapy are the mainstay of treatment, while exercise training is ...
| PowerPoint PPT presentation | free to view
Hyperlipidemia/Dyslipidemia PowerPoint PPT Presentation
Hyperlipidemia/Dyslipidemia - Hyperlipidemia/Dyslipidemia J.B. Handler, M.D. ... * Statins - Side Effects Increase in serum transaminase levels- must be monitored closely initial year.
Hyperlipidemia/Dyslipidemia J.B. Handler, M.D. ... * Statins - Side Effects Increase in serum transaminase levels- must be monitored closely initial year.
| PowerPoint PPT presentation | free to download
CARDIOVASCULAR DRUGS!!!!! PowerPoint PPT Presentation
CARDIOVASCULAR DRUGS!!!!! - CARDIOVASCULAR DRUGS!!!!! Adenosine MOA Increased K efflux: hyperpolarization. Drug of choice for which conditions? AV nodal arrhythmias. Short or long acting?
CARDIOVASCULAR DRUGS!!!!! Adenosine MOA Increased K efflux: hyperpolarization. Drug of choice for which conditions? AV nodal arrhythmias. Short or long acting?
| PowerPoint PPT presentation | free to download
Diabetic Dyslipidemia PowerPoint PPT Presentation
Diabetic Dyslipidemia - Diabetic Dyslipidemia Atherosclerosis in Diabetes ~80% of all diabetic mortality 75% from coronary atherosclerosis 25% from cerebral or peripheral vascular disease ...
Diabetic Dyslipidemia Atherosclerosis in Diabetes ~80% of all diabetic mortality 75% from coronary atherosclerosis 25% from cerebral or peripheral vascular disease ...
| PowerPoint PPT presentation | free to download
Approach to Dyslipidemia PowerPoint PPT Presentation
Approach to Dyslipidemia - Approach to Dyslipidemia Dr Zuhair M Shawagfeh FRCPI ... pravastatin or rosuvastatin Less drug interactions: pravastatin, fluvastatin, rosuvastatin ...
Approach to Dyslipidemia Dr Zuhair M Shawagfeh FRCPI ... pravastatin or rosuvastatin Less drug interactions: pravastatin, fluvastatin, rosuvastatin ...
| PowerPoint PPT presentation | free to download
DYSLIPIDEMIAS: TYPES I-V PowerPoint PPT Presentation
DYSLIPIDEMIAS: TYPES I-V - diabetic dyslipidemia frequently characterized by triglycerides, hdl and small, dense ldl. rx of diabetic dyslipidemia may reduce risk of chd.
diabetic dyslipidemia frequently characterized by triglycerides, hdl and small, dense ldl. rx of diabetic dyslipidemia may reduce risk of chd.
| PowerPoint PPT presentation | free to view
Monitoring Drug Efficacy PowerPoint PPT Presentation
Monitoring Drug Efficacy - Monitoring Drug Efficacy & Toxicity - along with drug metabolism Michael E. Hodsdon, MD, PhD Associate Professor Departments of Laboratory Medicine & Pharmacology
Monitoring Drug Efficacy & Toxicity - along with drug metabolism Michael E. Hodsdon, MD, PhD Associate Professor Departments of Laboratory Medicine & Pharmacology
| PowerPoint PPT presentation | free to download
Role of Fenofibrate in Diabetic  Dyslipidemia PowerPoint PPT Presentation
Role of Fenofibrate in Diabetic Dyslipidemia - Role of Fenofibrate in Diabetic Dyslipidemia Diabetic Dyslipidaemia Occurs in type 2 diabetes mellitus High levels of triglycerides Low levels of HDL-C LDL-C not ...
Role of Fenofibrate in Diabetic Dyslipidemia Diabetic Dyslipidaemia Occurs in type 2 diabetes mellitus High levels of triglycerides Low levels of HDL-C LDL-C not ...
| PowerPoint PPT presentation | free to download
Diabetic Dyslipidemia PowerPoint PPT Presentation
Diabetic Dyslipidemia - DAIS: Impact of Aggressive Therapy on Atherosclerosis in Patients With Type 2 Diabetes ... DAIS=Diabetes Atherosclerosis Intervention Study. Steiner G et al. Am ...
DAIS: Impact of Aggressive Therapy on Atherosclerosis in Patients With Type 2 Diabetes ... DAIS=Diabetes Atherosclerosis Intervention Study. Steiner G et al. Am ...
| PowerPoint PPT presentation | free to view
ANTI-VIRAL DRUGS PowerPoint PPT Presentation
ANTI-VIRAL DRUGS - ... Entry inhibitors Enfuvirtide (fusion inhibitor); Maraviroc (CCR5 receptor antagonist); Drugs for Viral Hepatitis Interferons , , ...
... Entry inhibitors Enfuvirtide (fusion inhibitor); Maraviroc (CCR5 receptor antagonist); Drugs for Viral Hepatitis Interferons , , ...
| PowerPoint PPT presentation | free to view
????(?) -New Drugs of 2001-2004 Review- PowerPoint PPT Presentation
????(?) -New Drugs of 2001-2004 Review- - New agents for Dyslipidemia. Ezetimibe. Rosuvastatin. New Drugs for ... ( by adrenal gland, vasculature, and heart) Eplerenone. Eplerenone. Pharmacology (cont. ...
New agents for Dyslipidemia. Ezetimibe. Rosuvastatin. New Drugs for ... ( by adrenal gland, vasculature, and heart) Eplerenone. Eplerenone. Pharmacology (cont. ...
| PowerPoint PPT presentation | free to view
Dyslipidemia – Pipeline Review, H2 2014 PowerPoint PPT Presentation
Dyslipidemia – Pipeline Review, H2 2014 - Complete report is available @ http://goo.gl/ct9R9m . This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects.
Complete report is available @ http://goo.gl/ct9R9m . This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects.
| PowerPoint PPT presentation | free to download
Diabetic Dyslipidemia PowerPoint PPT Presentation
Diabetic Dyslipidemia - 1999 Professional Postgraduate Services National Diabetes Data Group. ... 80% of all diabetic mortality. 75% from ... Postprandial (2 hr) plasma glucose ...
1999 Professional Postgraduate Services National Diabetes Data Group. ... 80% of all diabetic mortality. 75% from ... Postprandial (2 hr) plasma glucose ...
| PowerPoint PPT presentation | free to download
ANTIANGINAL (CORONARY ACTIVE) DRUGS PowerPoint PPT Presentation
ANTIANGINAL (CORONARY ACTIVE) DRUGS - Title: ( ) Author: intel09 Last modified by: Ekaterina Created Date: 10/31/2003 9:20:22 AM
Title: ( ) Author: intel09 Last modified by: Ekaterina Created Date: 10/31/2003 9:20:22 AM
| PowerPoint PPT presentation | free to view
Antihypertensive Drugs PowerPoint PPT Presentation
Antihypertensive Drugs - Elevation of arterial blood pressure above 140/90 mm Hg. Can be caused by: ... Ageusia. Skin rash. Proteinuria. Neutropenia. Pharmacology of AT-Receptor Antagonists ...
Elevation of arterial blood pressure above 140/90 mm Hg. Can be caused by: ... Ageusia. Skin rash. Proteinuria. Neutropenia. Pharmacology of AT-Receptor Antagonists ...
| PowerPoint PPT presentation | free to view
Approach to Dyslipidemia PowerPoint PPT Presentation
Approach to Dyslipidemia - Calculate non-HDL and goal is 30 above LDL goal Fibrates and nicotinic acid are good choices for elevated TG Hyperlipidemia in Nephrotic Syndrome Marked ...
Calculate non-HDL and goal is 30 above LDL goal Fibrates and nicotinic acid are good choices for elevated TG Hyperlipidemia in Nephrotic Syndrome Marked ...
| PowerPoint PPT presentation | free to download
Management of Dyslipidemia PowerPoint PPT Presentation
Management of Dyslipidemia - Consultant of Internal Medicine & Clinical Lipidology, ... Skin: no tendon xanthoma. TC: 240 mg/dl. TG: 190 mg/dl. HDL: 32 mg/dl. LDL: 170 mg/dl ...
Consultant of Internal Medicine & Clinical Lipidology, ... Skin: no tendon xanthoma. TC: 240 mg/dl. TG: 190 mg/dl. HDL: 32 mg/dl. LDL: 170 mg/dl ...
| PowerPoint PPT presentation | free to view
Dyslipidemia/Lipid management in Diabetes PowerPoint PPT Presentation
Dyslipidemia/Lipid management in Diabetes - Dyslipidemia/Lipid management in Diabetes
Dyslipidemia/Lipid management in Diabetes
| PowerPoint PPT presentation | free to download
Lipid-lowering drugs PowerPoint PPT Presentation
Lipid-lowering drugs - Lipid-lowering drugs Prof. MUDr Ji ina Mart nkov , PhD 2006/2007 Atherosclerosis and lipoprotein metabolism Atherosclerosis and lipoprotein metabolism LIPIDS ...
Lipid-lowering drugs Prof. MUDr Ji ina Mart nkov , PhD 2006/2007 Atherosclerosis and lipoprotein metabolism Atherosclerosis and lipoprotein metabolism LIPIDS ...
| PowerPoint PPT presentation | free to view
Side effects of antiretroviral drugs PowerPoint PPT Presentation
Side effects of antiretroviral drugs - Side effects of antiretroviral drugs Outi Vehvil inen, MD Ilembula Lutheran Hospital 31.1.2014 Outi Vehvil inen Outi Vehvil inen Outi Vehvil inen Outi ...
Side effects of antiretroviral drugs Outi Vehvil inen, MD Ilembula Lutheran Hospital 31.1.2014 Outi Vehvil inen Outi Vehvil inen Outi Vehvil inen Outi ...
| PowerPoint PPT presentation | free to download
Dyslipidemias    Practice Approach PowerPoint PPT Presentation
Dyslipidemias Practice Approach - Role of Cholesterol. Necessary component of Cell membranes. These essential envelopes protect the cell from its external (extracellular) environment and help maintain ...
Role of Cholesterol. Necessary component of Cell membranes. These essential envelopes protect the cell from its external (extracellular) environment and help maintain ...
| PowerPoint PPT presentation | free to view
Lipid-lowering drugs PowerPoint PPT Presentation
Lipid-lowering drugs - Lipid-lowering drugs 2011 Mgr. Petra Hirsova Plasma lipids Cholesterol, triglycerides, phospholipids, free fatty acids Transported as lipoproteins Core hydrofobic ...
Lipid-lowering drugs 2011 Mgr. Petra Hirsova Plasma lipids Cholesterol, triglycerides, phospholipids, free fatty acids Transported as lipoproteins Core hydrofobic ...
| PowerPoint PPT presentation | free to view
DYSLIPIDEMIA IN ADULTS WITH DIABETES* PowerPoint PPT Presentation
DYSLIPIDEMIA IN ADULTS WITH DIABETES* - ... with high risk for vascular disease, and aggressive lipid management is generally necessary. Attention to the full lipid profile is required, ...
... with high risk for vascular disease, and aggressive lipid management is generally necessary. Attention to the full lipid profile is required, ...
| PowerPoint PPT presentation | free to download
Drugs that affect the Cardiovascular System PowerPoint PPT Presentation
Drugs that affect the Cardiovascular System - Classification of Ischemic Heart Disease Acute coronary syndromes 1) Drugs that Affect Blood Coagulation Used in the prevention and management of thrombotic and ...
Classification of Ischemic Heart Disease Acute coronary syndromes 1) Drugs that Affect Blood Coagulation Used in the prevention and management of thrombotic and ...
| PowerPoint PPT presentation | free to download
Global Cardiovascular Disease Drugs Market Future Outlook, Market Analysis - Ken Research PowerPoint PPT Presentation
Global Cardiovascular Disease Drugs Market Future Outlook, Market Analysis - Ken Research - The Cardiovascular Disease (CVD) therapy area encompasses a range of different diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dyslipidemia, which accelerate the development of atherosclerotic plaque build up within blood vessels. For more information on the research report, refer to below link:- https://www.kenresearch.com/healthcare/pharmaceuticals/global-cardiovascular-disease-drugs-market-to-2023/142623-91.html
The Cardiovascular Disease (CVD) therapy area encompasses a range of different diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dyslipidemia, which accelerate the development of atherosclerotic plaque build up within blood vessels. For more information on the research report, refer to below link:- https://www.kenresearch.com/healthcare/pharmaceuticals/global-cardiovascular-disease-drugs-market-to-2023/142623-91.html
| PowerPoint PPT presentation | free to download
How To Get Off Diabetic Drugs: What the evidence shows PowerPoint PPT Presentation
How To Get Off Diabetic Drugs: What the evidence shows - How To Get Off Diabetic Drugs: What the evidence shows Sherry A. Rogers, M.D., ABEM, ABFP, ACAAI, FACN Prestigepublishing.com None of this is new, just ignored As an ...
How To Get Off Diabetic Drugs: What the evidence shows Sherry A. Rogers, M.D., ABEM, ABFP, ACAAI, FACN Prestigepublishing.com None of this is new, just ignored As an ...
| PowerPoint PPT presentation | free to download
Pharmacy Perspectives: Dyslipidemia PowerPoint PPT Presentation
Pharmacy Perspectives: Dyslipidemia - Ms. Lesley presents to the pharmacy after receiving the results of the lab test ... The new Canadian Cardiovascular Society position statement Recommendations for ...
Ms. Lesley presents to the pharmacy after receiving the results of the lab test ... The new Canadian Cardiovascular Society position statement Recommendations for ...
| PowerPoint PPT presentation | free to view
Dyslipidemia update by Dr Sarma PowerPoint PPT Presentation
Dyslipidemia update by Dr Sarma - Title: Dyslipidemia update by Dr Sarma Author: Dr Sarma Last modified by: said Created Date: 9/23/2003 2:44:29 PM Document presentation format: On-screen Show (4:3)
Title: Dyslipidemia update by Dr Sarma Author: Dr Sarma Last modified by: said Created Date: 9/23/2003 2:44:29 PM Document presentation format: On-screen Show (4:3)
| PowerPoint PPT presentation | free to download
Dyslipidemia Dx. Rx. by Dr Sarma PowerPoint PPT Presentation
Dyslipidemia Dx. Rx. by Dr Sarma - Welcome to You All Dr.Sarma@works * * Treatment of hyperlipidemia Statins have been and remain the drugs of first choice for lowering LDL-C.
Welcome to You All Dr.Sarma@works * * Treatment of hyperlipidemia Statins have been and remain the drugs of first choice for lowering LDL-C.
| PowerPoint PPT presentation | free to download
??????:????????? Pharmacy Practice Skills: Drug-Related Problems Solving PowerPoint PPT Presentation
??????:????????? Pharmacy Practice Skills: Drug-Related Problems Solving - Title: Pharmacy Practice Skills: Drug-Related Problems Solving Author: hitachi Last modified by
Title: Pharmacy Practice Skills: Drug-Related Problems Solving Author: hitachi Last modified by
| PowerPoint PPT presentation | free to download
Drugs for Lipid Disorders PowerPoint PPT Presentation
Drugs for Lipid Disorders - Low density lipoproteins (LDL) contribute to deposition of blockages in ... Improves all lipoprotein abnormalities. Side effect: flushing, GI complaints ...
Low density lipoproteins (LDL) contribute to deposition of blockages in ... Improves all lipoprotein abnormalities. Side effect: flushing, GI complaints ...
| PowerPoint PPT presentation | free to view
Coronary Artery Disease and Dyslipidemia PowerPoint PPT Presentation
Coronary Artery Disease and Dyslipidemia - Dallas, TX: American Heart Association, 2000. Prevalence: ... Diet & Lifestyle if over goals. Drug therapy if over goals by 30mg/dL ...
Dallas, TX: American Heart Association, 2000. Prevalence: ... Diet & Lifestyle if over goals. Drug therapy if over goals by 30mg/dL ...
| PowerPoint PPT presentation | free to view
Management of dyslipidemia Pathogenestic consideration. PowerPoint PPT Presentation
Management of dyslipidemia Pathogenestic consideration. - Laboratory findings: FBG: 170mg/dl (300 before metformin). HbA1c: 8.5%. TC: 284mg/dl. HDLc: 29mg/dl TG: 432mg/dl. Does she have the metabolic syndrome? 1. Yes 2 ...
Laboratory findings: FBG: 170mg/dl (300 before metformin). HbA1c: 8.5%. TC: 284mg/dl. HDLc: 29mg/dl TG: 432mg/dl. Does she have the metabolic syndrome? 1. Yes 2 ...
| PowerPoint PPT presentation | free to download
Dyslipidemia: When Statins Fail PowerPoint PPT Presentation
Dyslipidemia: When Statins Fail - Assistant Professor of Family Medicine and. Adjunct Faculty ... Nonsmoker. 0. 0. 0. 0. 0. Smoker. 8. 5. 3. 1. 1. Step 4: Systolic Blood Pressure. Step 5: Smoking ...
Assistant Professor of Family Medicine and. Adjunct Faculty ... Nonsmoker. 0. 0. 0. 0. 0. Smoker. 8. 5. 3. 1. 1. Step 4: Systolic Blood Pressure. Step 5: Smoking ...
| PowerPoint PPT presentation | free to download
Dyslipidemia in the Metabolic Syndrome: Can 1 agent treat all? PowerPoint PPT Presentation
Dyslipidemia in the Metabolic Syndrome: Can 1 agent treat all? - Dyslipidemia in the Metabolic Syndrome: Can 1 agent treat all? Brian Tulloch, M.D. Diagnostic Clinic Houston, Texas
Dyslipidemia in the Metabolic Syndrome: Can 1 agent treat all? Brian Tulloch, M.D. Diagnostic Clinic Houston, Texas
| PowerPoint PPT presentation | free to download
ATP III Guidelines Specific Dyslipidemias PowerPoint PPT Presentation
ATP III Guidelines Specific Dyslipidemias - ATP III Guidelines Specific Dyslipidemias Specific Dyslipidemias: Very High LDL Cholesterol ( 190 mg/dL) Causes and Diagnosis Genetic disorders Monogenic familial ...
ATP III Guidelines Specific Dyslipidemias Specific Dyslipidemias: Very High LDL Cholesterol ( 190 mg/dL) Causes and Diagnosis Genetic disorders Monogenic familial ...
| PowerPoint PPT presentation | free to download
MACROVASCULAR COMPLICATIONS, DYSLIPIDEMIA and HYPERTENSION PowerPoint PPT Presentation
MACROVASCULAR COMPLICATIONS, DYSLIPIDEMIA and HYPERTENSION - 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada MACROVASCULAR COMPLICATIONS, DYSLIPIDEMIA and HYPERTENSION
2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada MACROVASCULAR COMPLICATIONS, DYSLIPIDEMIA and HYPERTENSION
| PowerPoint PPT presentation | free to download
Hypertension and Dyslipidemia An ominous PowerPoint PPT Presentation
Hypertension and Dyslipidemia An ominous - Events * in the Major Prevention Trials Lowering LDL-C Is Not Enough AZ-40 UTI.ppt Hypertension and Dyslipidemia An ominous and common combination NED ...
Events * in the Major Prevention Trials Lowering LDL-C Is Not Enough AZ-40 UTI.ppt Hypertension and Dyslipidemia An ominous and common combination NED ...
| PowerPoint PPT presentation | free to view
DYSLIPIDEMIA IN ADULTS WITH DIABETES* PowerPoint PPT Presentation
DYSLIPIDEMIA IN ADULTS WITH DIABETES* - This entails adopting healthy eating ... IN ADULTS WITH DIABETES* 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada ...
This entails adopting healthy eating ... IN ADULTS WITH DIABETES* 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada ...
| PowerPoint PPT presentation | free to download
Global Cardiovascular Disease Drugs Market Forecast - Ken Research PowerPoint PPT Presentation
Global Cardiovascular Disease Drugs Market Forecast - Ken Research - The Cardiovascular Disease (CVD) therapy area encompasses a range of different diseases and conditions affecting the heart and/or blood vessels... To know more, click on the link below: https://www.kenresearch.com/healthcare/pharmaceuticals/global-cardiovascular-disease-drugs-market-to-2023/142623-91.html
The Cardiovascular Disease (CVD) therapy area encompasses a range of different diseases and conditions affecting the heart and/or blood vessels... To know more, click on the link below: https://www.kenresearch.com/healthcare/pharmaceuticals/global-cardiovascular-disease-drugs-market-to-2023/142623-91.html
| PowerPoint PPT presentation | free to download
ANTIHYPERTENSIVES, DIURETICS, ANTICOAGULANTS AND DYSLIPIDEMICS PowerPoint PPT Presentation
ANTIHYPERTENSIVES, DIURETICS, ANTICOAGULANTS AND DYSLIPIDEMICS - Hx of DVT or Pe. Cigarrette smoking. Immobility. Overview of cholesterol panel. Total cholesterol ... Classes of agents include: HMB-CoA reductase inhibitors or ' ...
Hx of DVT or Pe. Cigarrette smoking. Immobility. Overview of cholesterol panel. Total cholesterol ... Classes of agents include: HMB-CoA reductase inhibitors or ' ...
| PowerPoint PPT presentation | free to download
ATP III Guidelines Specific Dyslipidemias PowerPoint PPT Presentation
ATP III Guidelines Specific Dyslipidemias - Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults Author: RClark Last modified by: CHagan Created Date:
Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults Author: RClark Last modified by: CHagan Created Date:
| PowerPoint PPT presentation | free to download
Drugs for Lipid Disorders PowerPoint PPT Presentation
Drugs for Lipid Disorders - Identify the most commonly known sterol and discuss its ... Cholestyramine- mix powder as directed; do not inhale powder. Bile Acid Resins: Patient Teaching ...
Identify the most commonly known sterol and discuss its ... Cholestyramine- mix powder as directed; do not inhale powder. Bile Acid Resins: Patient Teaching ...
| PowerPoint PPT presentation | free to view
Controversial issues in dyslipidemia management PowerPoint PPT Presentation
Controversial issues in dyslipidemia management - In this study, after a six- to eight-week washout period, patients with mixed hyperlipidemia LDL cholesterol between 130 and 220 mg/dL ...
In this study, after a six- to eight-week washout period, patients with mixed hyperlipidemia LDL cholesterol between 130 and 220 mg/dL ...
| PowerPoint PPT presentation | free to download
DYSLIPIDEMIA IN ADULTS WITH DIABETES* PowerPoint PPT Presentation
DYSLIPIDEMIA IN ADULTS WITH DIABETES* - lovastatin (Mevachor and generic) - pravastatin (Pravachol and generic) - rosuvastatin (Crestor) ... simvastatin (Zocor and generic) CDA CPG *Expert Committee. ...
lovastatin (Mevachor and generic) - pravastatin (Pravachol and generic) - rosuvastatin (Crestor) ... simvastatin (Zocor and generic) CDA CPG *Expert Committee. ...
| PowerPoint PPT presentation | free to download
Use of Antipsychotic Drugs in Dementia PowerPoint PPT Presentation
Use of Antipsychotic Drugs in Dementia - University of Florida Departments of Psychiatry and Neurology ... out of 17 placebo-controlled trials showed numerical increases in mortality in ...
University of Florida Departments of Psychiatry and Neurology ... out of 17 placebo-controlled trials showed numerical increases in mortality in ...
| PowerPoint PPT presentation | free to download
Chapter 5 Drugs for Diabetes Mellitus PowerPoint PPT Presentation
Chapter 5 Drugs for Diabetes Mellitus - Diet. Exercise. Insulin Administration. Injection. Oral anti-diabetic agents. 19. Diet. Timing of food intake ... Diabetic Concerns. Diabetic ketoacidosis ...
Diet. Exercise. Insulin Administration. Injection. Oral anti-diabetic agents. 19. Diet. Timing of food intake ... Diabetic Concerns. Diabetic ketoacidosis ...
| PowerPoint PPT presentation | free to view
Dyslipidemia and Insulin Resistance in Pediatric HIV PowerPoint PPT Presentation
Dyslipidemia and Insulin Resistance in Pediatric HIV - Dyslipidemia and Insulin Resistance in Pediatric HIV Infection: Implications for Cardiovascular Health George K. Siberry, MD, MPH Pediatric Maternal AIDS (PAMA) Branch
Dyslipidemia and Insulin Resistance in Pediatric HIV Infection: Implications for Cardiovascular Health George K. Siberry, MD, MPH Pediatric Maternal AIDS (PAMA) Branch
| PowerPoint PPT presentation | free to view
Addictions in the Older Adult Alcohol, Drugs, Gambling PowerPoint PPT Presentation
Addictions in the Older Adult Alcohol, Drugs, Gambling - Addictions in the Older Adult Alcohol, Drugs, Gambling Michelle Gibson, MD, CCFP, COE Queen s University, Geriatric Medicine Specialized Geriatric Services
Addictions in the Older Adult Alcohol, Drugs, Gambling Michelle Gibson, MD, CCFP, COE Queen s University, Geriatric Medicine Specialized Geriatric Services
| PowerPoint PPT presentation | free to view
Hypertension: Which Drug? Psirropoulos Dimitrios Z, MD, PhD PowerPoint PPT Presentation
Hypertension: Which Drug? Psirropoulos Dimitrios Z, MD, PhD - Hypertension: Which Drug? Psirropoulos Dimitrios Z, MD, PhD Head Director, Cardiology Department & CCU G. Gennimatas General Hospital Thessaloniki, Greece
Hypertension: Which Drug? Psirropoulos Dimitrios Z, MD, PhD Head Director, Cardiology Department & CCU G. Gennimatas General Hospital Thessaloniki, Greece
| PowerPoint PPT presentation | free to view
Dyslipidemia and Cardiovascular Risk Reduction: An Evidence-Based Review PowerPoint PPT Presentation
Dyslipidemia and Cardiovascular Risk Reduction: An Evidence-Based Review - Title: Managing Dyslipidemia Author: Margit Rezabek Last modified by: momealy Created Date: 2/4/2007 4:16:17 AM Document presentation format: On-screen Show
Title: Managing Dyslipidemia Author: Margit Rezabek Last modified by: momealy Created Date: 2/4/2007 4:16:17 AM Document presentation format: On-screen Show
| PowerPoint PPT presentation | free to download
Suboptimal Drug Use in Long Term Care Facility Patients PowerPoint PPT Presentation
Suboptimal Drug Use in Long Term Care Facility Patients - List the different types of suboptimal drug use. Describe the prevalence of polypharmacy (9 drugs) ... SSRI tramadol, st john wort. Sulfonylureas imidazoles ...
List the different types of suboptimal drug use. Describe the prevalence of polypharmacy (9 drugs) ... SSRI tramadol, st john wort. Sulfonylureas imidazoles ...
| PowerPoint PPT presentation | free to download
Page of  


PowerPlugs
PowerPlugs
View by Category
Presentations
  • Photo Slideshows
  • Presentations (free-to-view)
    • Concepts & Trends
    • Entertainment
    • Fashion & Beauty
    • Government & Politics
    • How To, Education & Training
    • Medicine, Science & Technology
    • Other
    • Pets & Animals
    • Products & Services
    • Religious & Philosophical
    • Travel & Places
  • Presentations (pay-to-view)
Products Sold on our sister site CrystalGraphics.com
  • Ultimate Combo for PPT
  • PowerPoint Templates
  • Charts & Diagrams for PPT
  • 3D Character Slides
  • Background Videos for PPT
  • More Products for PPT
PowerPlugs
PowerPlugs
CrystalGraphics
Home About Us Terms and Conditions Privacy Policy Contact Us Send Us Feedback
Copyright 2021 CrystalGraphics, Inc. — All rights Reserved. PowerShow.com is a trademark of CrystalGraphics, Inc.
dyslipidemia drug — Search results on PowerShow.com
Loading...